OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
Xiaoqing Yan, Ming Ye, Qing Zou, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 190-199
Open Access | Times Cited: 36
Xiaoqing Yan, Ming Ye, Qing Zou, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 190-199
Open Access | Times Cited: 36
Showing 26-50 of 36 citing articles:
Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors
Yong Zhou, Zhengcheng Liu, Ao Yu, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 813-829
Open Access | Times Cited: 1
Yong Zhou, Zhengcheng Liu, Ao Yu, et al.
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 813-829
Open Access | Times Cited: 1
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
Shuo Kang, Jintuo Yin
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 5, pp. 653-659
Closed Access
Shuo Kang, Jintuo Yin
Expert Review of Pharmacoeconomics & Outcomes Research (2024) Vol. 24, Iss. 5, pp. 653-659
Closed Access
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?
Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 411-414
Open Access
Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 6, pp. 411-414
Open Access
Toripalimab in combination with chemotherapy effectively suppresses local recurrence and metastatic sarcomatoid renal cell carcinoma: A case report
Mingzhu Gao, Nianfei Wang, Jinyou Wang, et al.
World Journal of Clinical Cases (2024) Vol. 12, Iss. 28, pp. 6230-6236
Open Access
Mingzhu Gao, Nianfei Wang, Jinyou Wang, et al.
World Journal of Clinical Cases (2024) Vol. 12, Iss. 28, pp. 6230-6236
Open Access
Efficacy and safety of neoadjuvant therapy with tislelizumab plus axitinib for nonmetastatic renal cell carcinoma with inferior vena cava tumor thrombus: a retrospective study
Zhongjie Zhao, Zhengsheng Liu, Kaiyan Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Zhongjie Zhao, Zhengsheng Liu, Kaiyan Zhang, et al.
Research Square (Research Square) (2024)
Open Access
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review
Julia Sprokkerieft, Justine N. van der Beek, Filippo Spreafico, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104523-104523
Open Access
Julia Sprokkerieft, Justine N. van der Beek, Filippo Spreafico, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104523-104523
Open Access
N6-methyladenosine-modified TRIM37 augments sunitinib resistance by promoting the ubiquitin-degradation of SmARCC2 and activating the Wnt signaling pathway in renal cell carcinoma
Qiang Luo, Ting Dai, Yihong Dong, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access
Qiang Luo, Ting Dai, Yihong Dong, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database
Hatice Bölek, Elif Sertesen, Omer F. Kuzu, et al.
Clinical Genitourinary Cancer (2024) Vol. 23, Iss. 1, pp. 102282-102282
Closed Access
Hatice Bölek, Elif Sertesen, Omer F. Kuzu, et al.
Clinical Genitourinary Cancer (2024) Vol. 23, Iss. 1, pp. 102282-102282
Closed Access
Application of extended immunotherapy in advanced clear cell renal cell carcinoma treated with first-line combination of immune-checkpoint inhibitor and tyrosine kinase inhibitor
Qian Wang, Xingming Zhang, Qiyu Zhu, et al.
Research Square (Research Square) (2024)
Closed Access
Qian Wang, Xingming Zhang, Qiyu Zhu, et al.
Research Square (Research Square) (2024)
Closed Access
Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review)
Giorgia Isinelli, S. Failla, Roberto Plebani, et al.
Medicine International (2024) Vol. 5, Iss. 2
Closed Access
Giorgia Isinelli, S. Failla, Roberto Plebani, et al.
Medicine International (2024) Vol. 5, Iss. 2
Closed Access
Novel voice of targeted therapy combination with immunotherapy for advanced renal cell carcinoma from China
Xiongjun Ye
Chinese Science Bulletin (Chinese Version) (2023) Vol. 69, Iss. 8, pp. 968-970
Open Access
Xiongjun Ye
Chinese Science Bulletin (Chinese Version) (2023) Vol. 69, Iss. 8, pp. 968-970
Open Access
